Clinical Care Options presents a new "Interactive Decision Support Tool" for Hepatitis B consultations to help determine whether and how to treat HBV patients, "Hep B Consult: US, European, and Asia-Pacific Guideline Recommendations on Whether and How to Treat HBV" Downloading this tool is FREE but requires that you register with Clinical Care Options website: https://www.clinicaloptions.com/hepatitis/programs/2019-hbv-management/idst/tool Source: B
Clinical Care Options presents three new seminars in their HCV Elimination 2018 series, each one dealing with a population particularly at risk of acquiring or passing on HCV: Men Who Have Sex with Men [MSM] - ACCESS INFORMATION BELOW Persons Who Inject Drugs [PWID] - SEE ACCESS INFORMATION IN SEPARATE ARTICLE, and People Who Are Incarcerated [COMING SOON] The MSM module is introduced below... CCO CME/CE-certified interactive video module
Clinical Care Options presents three new seminars in their HCV Elimination 2018 series, each one dealing with a population particularly at risk of acquiring or passing on HCV: Persons Who Inject Drugs, [PWID] - ACCESS INFORMATION BELOW. Men Who Have Sex with Men [MSM] - SEE ACCESS INFORMATION IN SEPARATE ARTICLE, and People Who Are Incarcerated [COMING SOON] The PWID module is introduced below... CCO CME/CE-certified interactive video modu
Congratulations, hepatitis C patients in BC, BC PharmaCare, and AbbVie Pharmaceuticals! One more treatment option is now available to BC HCV patients of all genotypes, New patients without cirrhosis need only 8 weeks treatment. Maviret™ is also safe and effective for the many HCV+ people with chronic kidney disease (CKD). More information: https://www.newswire.ca/news-releases/british-columbia-pharmacare-lists-abbvie-s-hepatitis-c-treatment-mavi...
Friday, Feb. 22, 2019 News Recap: Time to Change Protocols for Post-SVR Monitoring for Liver Cancer? In Memoriam: Anita York (May 27, 1953 - Feb. 7, 2019) Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV) MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring
Finally, Maviret, AbbVie's hepatitis C drug, has made it through Canada's approval process and has been listed for coverage by Ontario's PharmaCare. We hope BC PharmaCare will also list it soon. "MAVIRET™ is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment (from: Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016 and 2017)... MA...
Funding of up to $2500 is available to support women's self-directed health and education ideas...to improve health, wellness, skills building and social connectivity." More Information at... https://www.vancouverfriendsforlife.ca/women-s-welleness-project First deadline: March 15, 2019 (results announced March 30th)
Current protocols for HCV post-SVR monitoring may need updating to expand screening for liver cancer to those without cirrhosis. This article is dedicated to all non-cirrhotics who have been diagnosed with liver cancer following treatment for HCV. HepCBC's volunteer Webmaster, CD Mazoff, PhD (discourse analysis, McGill), is battling liver cancer (HCC). For several years, CD has faithfully published the online HepCBC Weekly Bull every Friday, showcasing Ca
Anita York: May 27, 1953 - Feb. 7, 2019 Our beautiful friend, Anita York (May 27, 1953 - Feb. 7, 2019), was honoured Feb. 17, 2019 in a private family ceremony. HepCBC, for whom she worked for many years as a key volunteer and as a Coordinator of Volunteers, is mourning the loss of this outspoken peer advocate, always ready to battle for anyone fighting hepatitis C, or to prevent even one more person from suffering from this debilitating disease. A...
Friday, Jan 25, 2019 News Recap: Using Telemedicine HCV Care Model in Prisons in SPAIN “HCV telemedicine program satisfying, cost-effective in Spanish prison: A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018…” Read more about Spain’s prison-based HCV “Telemedicine” treatment model. Saturday in Surrey! Visit HepC